Azitra, Inc. (AZTR)

USD 0.38

(-9.91%)

Operating Expenses Summary of Azitra, Inc.

  • Azitra, Inc.'s latest annual operating expenses in 2023 was 8.3 Million USD , down -14.74% from previous year.
  • Azitra, Inc.'s latest quarterly operating expenses in 2024 Q2 was 2.55 Million USD , down -9.92% from previous quarter.
  • Azitra, Inc. reported a annual operating expenses of 9.73 Million USD in annual operating expenses 2022, up 4.35% from previous year.
  • Azitra, Inc. reported a annual operating expenses of 9.33 Million USD in annual operating expenses 2021, down 0.0% from previous year.
  • Azitra, Inc. reported a quarterly operating expenses of 2.96 Million USD for 2024 Q1, up 10.92% from previous quarter.
  • Azitra, Inc. reported a quarterly operating expenses of 2.3 Million USD for 2023 Q3, up 39.03% from previous quarter.

Annual Operating Expenses Chart of Azitra, Inc. (2023 - 2021)

Historical Annual Operating Expenses of Azitra, Inc. (2023 - 2021)

Year Operating Expenses Operating Expenses Growth
2023 8.3 Million USD -14.74%
2022 9.73 Million USD 4.35%
2021 9.33 Million USD 0.0%

Peer Operating Expenses Comparison of Azitra, Inc.

Name Operating Expenses Operating Expenses Difference
AIM ImmunoTech Inc. 32.07 Million USD 74.116%
Ampio Pharmaceuticals, Inc. 9.26 Million USD 10.419%
Armata Pharmaceuticals, Inc. 11.64 Million USD 28.729%
Actinium Pharmaceuticals, Inc. 52 Million USD 84.034%
Can-Fite BioPharma Ltd. 8.93 Million USD 7.111%
Chromocell Therapeutics Corporation 6.86 Million USD -20.986%
Calidi Biotherapeutics, Inc. 28.99 Million USD 71.363%
CEL-SCI Corporation 31.47 Million USD 73.623%
iBio, Inc. 16.85 Million USD 50.754%
Lineage Cell Therapeutics, Inc. 33 Million USD 74.847%
MAIA Biotechnology, Inc. 20.18 Million USD 58.863%
Matinas BioPharma Holdings, Inc. 24.86 Million USD 66.606%
Navidea Biopharmaceuticals, Inc. 13.93 Million USD 40.406%
NovaBay Pharmaceuticals, Inc. 12.89 Million USD 35.63%
NanoViricides, Inc. 8.51 Million USD 2.51%
Oragenics, Inc. 5.45 Million USD -52.283%
BiomX Inc. 26.81 Million USD 69.037%
BiomX Inc. 26.81 Million USD 69.037%
Protalix BioTherapeutics, Inc. 32.05 Million USD 74.097%
Palatin Technologies, Inc. 34.67 Million USD 76.053%
Scorpius Holdings, Inc. 39.81 Million USD 79.148%